Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2019 Dec 3;14:278. doi: 10.1186/s13023-019-1262-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — a Patient 1 presented with a cauliflower-like tumor at the right lower leg. The tumor did not regress after 4 cycles of cetuximab. b MRI and ¹⁸F-FGD-PET/CT at baseline showed hypermetabolic enlarged node metastases (white and black arrows, respectively) in the left axilla and pelvis (upper panel). Five months after cetuximab initiation a decrease of the axillary lymph node metastasis in size and metabolism was observed, while only a faint residuum was noticeable in the pelvic region (lower panel). Also note the increased bone marrow activity due to concomitant inflammatory reactions associated with the chronic wounds in EB. c IHC of the primary tumor of patient 1 revealed positive EGFR staining (red)